Overview

Afatinib in NSCLC With HER2 Mutation

Status:
Completed

Trial end date:
2018-07-22

Target enrollment:

Participant gender:

Summary

to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2 mutations, previously treated with 1 or 2 chemotherapy regimens

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Afatinib
Paclitaxel